Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


 - The Oxford AstraZeneca vaccine (and many other vaccines) take advantage of gene therapy technology too. 

- This chimpanzee adenoviral vector delivers a gene encoding for a coronavirus coat protein (SARS-CoV-2 Spike) to be expressed for a very short time.

- By introducing this coat protein as a target to immune cells, the vaccine facilitates them to recognise and fight a future coronavirus infection!


This is one example of how researchers are taking advantage of adenoviral vectors to generate vaccines.

 Adenoviral vectors:

  • Effective and efficient short-term and immunogenic expression.
  • Relatively large gene capacity.
  • Easy to produce high quantities.


 Click here to discover how an adenovirus is also being developed to fight cancer!



Other viral vectors are also being used or developed to treat disease: 




Find out more about the Oxford Astrazeneca vaccine

Find out more about the work of the Gill Hyde Gene Medicine research group at the University of Oxford.